The next generation of biologic agents: Therapeutic role in relation to existing therapies in metastatic breast cancer

Clinical Breast Cancer

Volumn 12, Issue 3, 2012, Pages 157-166

  Conte, Pierfranco ^a   Guarneri, Valentina ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Antibody; New agents; Targeted; Taxane

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERIBULIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IXABEPILONE; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PERTUZUMAB; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ANEMIA; ASTHENIA; BLEEDING; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL EVALUATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DNA REPAIR; DYSPNEA; FATIGUE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HAZARD RATIO; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEINURIA; RASH; REVIEW; SKIN MANIFESTATION;

EID: 84861169193     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.03.005     Document Type: Review

References (110)

1. S. Beslija, J. Bonneterre, H.J. Burstein Third consensus on medical treatment of metastatic breast cancer Ann Oncol 20 2009 1771 1785
2. R.H. Alvarez, V. Valero, G.N. Hortobagyi Emerging targeted therapies for breast cancer J Clin Oncol 28 2010 3366 3379
3. V. Guarneri, P. Conte Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy Oncologist 14 2009 645 656
4. A. Sánchez-Muñoz, E. Pérez-Ruiz, B. Jiménez Targeted therapy of metastatic breast cancer Clin Transl Oncol 11 2009 643 650
5. N. Quénel, J. Wafflart, F. Bonichon The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases Breast Cancer Res Treat 35 1995 283 291
6. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
7. M. Marty, F. Cognetti, D. Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 2005 4265 4274
8. M. Marty, F. Cognetti, D. Maraninchi Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving more than 4 years in the M77001 study Breast Cancer Res Treat 100 suppl 1 2006 abstract 2067
9. M. Andersson, E. Lidbrink, K. Bjerre Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study J Clin Oncol 29 2011 264 271
10. N. Robert, B. Leyland-Jones, L. Asmar Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer J Clin Oncol 24 2006 2786 2792
11. V. Valero, J. Forbes, M.D. Pegram Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens J Clin Oncol 29 2011 149 156
12. S. Moulder, H. Li, M. Wang A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group trial Breast Cancer Res Treat 119 2010 663 671
13. S. Dent, S.H. Verma, J. Latreille The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer Curr Oncol 16 2009 25 35
14. T. Bachelot, L. Mauriac, C. Delcambre Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression J Clin Oncol 25 suppl 2007 abstract 1094 www.asco.org Accessed: March 28, 2012
15. R. Bartsch, C. Wenzel, G. Altorjai Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer J Clin Oncol 25 2007 3853 3858
16. S. Del Bianco, R. Rondinelli Trastuzumab-containing therapies: activity beyond disease progression in M.B.C. - a pivotal experience J Clin Oncol 24 suppl 2006 abstract 10788
17. L. Orlando, A. Cardillo, R. Ghisini Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer BMC Cancer 6 2006 225 233
18. A. Morabito, R. Longo, D. Gattuso Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer Oncol Rep 16 2006 393 398
19. D. Tripathy, D.J. Slamon, M. Cobleigh Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression J Clin Oncol 22 2004 1063 1070
20. J.M. Extra, E.C. Antoine, A. Vincent-Salomon Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study Oncologist 15 2010 799 809
21. G. Cancello, E. Montagna, D. D'Agostino Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer Breast Cancer Res 10 2008 R60
22. G. von Minckwitz, A. du Bois, M. Schmidt Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 2009 1999 2006
23. G. Arpino, L. Wiechmann, C.K. Osborne Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocr Rev 29 2008 217 233
24. V. Guarneri Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer Expert Rev Anticancer Ther 9 2009 1549 1557
25. C.K. Osborne, V. Bardou, T.A. Hopp Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J Natl Cancer Inst 95 2003 353 361
26. M. De Laurentiis, G. Arpino, E. Massarelli A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer Clin Cancer Res 11 2005 4741 4748
27. F. Montemurro, V. Rossi, M. Cossu Rocca Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients Cancer 118 2012 17 26
28. B. Kaufman, J.R. Mackey, M.R. Clemens Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor+ metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 2009 5529 5537
29. E.R. Wood, A.T. Truesdale, O.B. McDonald A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res 64 2004 6652 6659
30. H.J. Burstein, A.M. Storniolo, S. Franco A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer Ann Oncol 19 2008 1068 1074
31. H.L. Gomez, D.C. Doval, M.A. Chavez Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer J Clin Oncol 26 2008 2999 3005
32. C.E. Geyer, J. Foster, D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 356 2006 2733 2743
33. D. Cameron, M. Casey, M. Press A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Res Treat 112 2008 533 543
34. S. Johnston, J. Pippen Jr, X. Pivot Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor+ metastatic breast cancer J Clin Oncol 27 2009 5538 5546
35. A. Frassoldati, V. Guarneri, F. Piacentini Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB) Clin Breast Cancer 8 2008 97 100
36. N.U. Lin, I.A. Mayer, N.S. Najita TBCRC 003: phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC) J Clin Oncol 29 suppl 2011 abstract 527 www.asco.org Accessed: March 28, 2012
37. K.L. Blackwell, H.J. Burstein, A.M. Storniolo Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 2010 1124 1130
38. K.L. Blackwell, H.L. Burstein, G.W. Sledge Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy Cancer Res (San Antonio Breast Cancer Symposium) 69 2009 abstract 61
39. K. Miller, M. Wang, J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
40. D.W. Miles, A. Chan, L.Y. Dirix Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 3239 3247
41. N.J. Robert, V. Diéras, J. Glaspy RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
42. A.M. Brufsky, S. Hurvitz, E. Perez RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 29 2011 4286 4293
43. J. O'Shaughnessy, V. Dieras, J. Glaspy Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer Cancer Res 69 suppl 1 2009 abstract 207
44. J. Cortes, V. Calvo, N. Ramírez-Merino Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis Ann Oncol 2011 Oct 4 [Epub ahead of print]
45. A. Brufsky, V. Valero, B. Tiangco Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of ribbon-2 J Clin Oncol 29 suppl 2011 abstract 1010 www.asco.org Accessed: March 28, 2012
46. Food and Drug Administration Proposal to Withdraw Approval for the Breast Cancer Indication For bevacizumab (Avastin) June 29, 2011 http://www.fda.gov/ downloads/NewsEvents/MeetingsConferencesWorkshops/UCM261699.pdf Accessed: July 6, 2011
47. V. Ranpura, S. Hapani, S. Wu Treatment-related mortality with bevacizumab in cancer patientsTreatment-related mortality with bevacizumab in cancer patients: a meta-analyssis JAMA 305 2011 487 494
48. Ixempra Ixabepilone injection [prescribing information] 2010 Bristol-Myers Squibb Company Princeton, NJ
49. E.A. Perez, G. Lerzo, X. Pivot Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 2007 3407 3414
50. H. Roché, L. Yelle, F. Cognetti Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 2007 3415 3420
51. E. Thomas, J. Tabernero, M. Fornier Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 2007 3399 3406
52. E.S. Thomas, H.L. Gomez, R.K. Li Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 2007 5210 5217
53. J.A. Sparano, E. Vrdoljak, O. Rixe Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 28 2010 3256 3263
54. H. Roché, P. Conte, E.A. Perez Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies Breast Cancer Res Treat 125 2011 755 765
55. Conte P, Roché H, Perez E, et al. Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. abstract 6114.
56. E.A. Perez, T. Patel, A. Moreno-Aspitia Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer Breast Cancer Res Treat 121 2010 261 271
57. P.F. Conte, V. Guarneri Triple-negative breast cancer: current management and future options Eur J Cancer Suppl 7 2009 14 18
58. H.S. Rugo, M. Campone, D. Amadori Randomized study of weekly vs every 3 week ixabepilone plus bevacizumab (ixa/bev) vs paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results J Clin Oncol 28 suppl 2010 Abstract 1040 www.asco.org Accessed: March 28, 2012
59. L. Gianni, A. Lladó, G. Bianchi Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 1131 1137
60. J. Baselga, K.A. Gelmon, S. Verma Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy J Clin Oncol 28 2010 1138 1144
61. L. Gianni, T. Pienkowski, Y.H. Im Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (neosphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 25 32
62. J. Baselga, J. Cortés, S.B. Kim Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
63. S. Modi, M. Beeram, I.E. Krop A phase I study of trastuzumab-DM1, a first-in-class HER2-antibody drug conjugate, in patients with advanced HER2 breast cancer J Clin Oncol 26 suppl 2008 abstract 1028
64. H.A. Burris, H.S. Rugo, S.J. Vukelja Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy J Clin Oncol 29 2011 398 405
65. Hurvitz SA, Dirix L, Kocsis J, et al. Trastuzumab emtansine (T-DM1) versus trastuzumabadocetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). Paper presented at: European Multidisciplinary Cancer Congress (ECCO/ESMO); September 23-27, 2011; Stockholm, Sweden. Abstract 5001.
66. Y. Yarden, M.X. Sliwkowski Untangling the ErbB signaling networkUntangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
67. D.J. Slamon, G.M. Clark, S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
68. A.L. Harris, S. Nicholson, J.R. Sainsbury Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu J Steroid Biochem 34 1989 123 131
69. J.G. Klijn, P.M. Berns, P.I. Schmitz The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients Endocr Rev 13 1992 3 17
70. S.B. Fox, K. Smith, J. Hollyer The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review for 3009 patientsThe epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients Breast Cancer Res Treat 29 1994 41 49
71. J. O'Shaughnessy, D. Weckstein, S. Vukelja Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer Breast Cancer Res Treat 106 suppl 1 2007 abstract 308
72. L. Carey, H. Rugo, P. Marcom TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal-like) breast cancer J Clin Oncol 26 suppl 2008 abstract 1009 www.asco.org Accessed: March 29, 2012
73. J. Baselga, P. Gomez, A. Awada The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1) Ann Oncol 21 suppl 8 2010 vii96 (abstract 274O)
74. M. Cristofanilli, R. Schiff, V. Valero Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib with placebo in combination with tamoxifen or anastrozole in hormone receptor+ metastatic breast cancer J Clin Oncol 27 suppl 2009 abstract 1014 www.asco.org Accessed: March 29, 2012
75. D. Strumberg, J.W. Clark, A. Awada Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 2007 426 437
76. G. Bianchi, S. Loibl, C. Zamagni A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer Eur J Cancer 3 suppl 2 2005 abstract 276
77. A. Moreno-Aspitia, D.W. Hillman, M. Wiesenfeld BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane J Clin Oncol 24 suppl 2006 abstract 577 www.asco.org Accessed: March 29, 2012
78. A. Moreno-Aspitia, R.F. Morton, D.W. Hillman Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic trial N0336 J Clin Oncol 27 2009 11 15
79. Gradishar WJ, Kaklamani V, Prasad Sahoo T, et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). Paper presented at: 32nd San Antonio Breast Cancer Symposium; December 9-13; San Antonio, TX. Abstract 44.
80. J. Baselga, J.G.M. Segalla, H. Roché Solti-0701: a double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced breast cancer (adv BC) Eur J Cancer 7 suppl 3 2009 abstract 3LBA
81. C. Hudis, K.W. Tauer, R.C. Hermann Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV) J Clin Oncol 29 suppl 2011 abstract 1009 www.asco.org Accessed: March 29, 2012
82. D.B. Mendel, A.D. Laird, X. Xin In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337
83. S. Faivre, C. Delbaldo, K. Vera Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 2006 25 35
84. H.J. Burstein, A.D. Elias, H.S. Rugo Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 2008 1810 1816
85. E.L. Mayer, S. Dhakil, T. Patel SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer Ann Oncol 21 2010 2371 2376
86. J. Crown, V. Dieras, E. Staroslawska Phase II trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC) J Clin Oncol 28 suppl 2010 abstract LBA 1011
87. J. Bergh, R. Greil, N. Voytko Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC) J Clin Oncol 28 suppl 2010 abstract LBA 1010
88. C.H. Barrios, M.C. Liu, S.C. Lee Phase III randomized trial of sunitinib vs. capecitabine in patients with previously treated HER2-negative advanced breast cancerPhase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer Breast Cancer Res Treat 121 2010 121 131
89. J.C. Montero, S. Seoane, A. Ocaña Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors Clin Cancer Res 17 2011 5546 5552
90. D. Tryfonopoulos, S. Walsh, D.M. Collins Src: a potential target for the treatment of triple-negative breast cancer Ann Oncol 22 2011 2234 2240
91. R.S. Finn, C. Bengala, N. Ibrahim Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study Clin Cancer Res 17 2011 6905 6913
92. C.I. Herold, V. Chadaram, B.L. Peterson Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing Clin Cancer Res 17 2011 6061 6070
93. E.L. Mayer, J.F. Baurain, J. Sparano A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor+ breast cancer Clin Cancer Res 17 2011 6897 6904
94. S. Moulder, K. Yan, F. Huang Development of candidate genomic markers to select breast cancer patients for dasatinib therapy Mol Cancer Ther 9 2010 1120 1127
95. B.T. Hennessy, D.L. Smith, P.T. Ram Exploiting the PI3K/AKT pathway for cancer drug discovery Nat Rev Drug Discov 4 2005 988 1004
96. S.J. Isakoff, J.A. Engelman, H.Y. Irie Breast cancer associated PI3KCA mutations are oncogenic in mammary epithelial cells Cancer Res 65 2006 10992 11000
97. A. Awada, F. Cardoso, C. Fontaine The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics Eur J Cancer 44 2008 84 91
98. F. Andre, M. Campone, R. O'Regan Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab J Clin Oncol 28 2010 5110 5115
99. S.L. Ellard, M. Clemons, K.A. Gelmon Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163 J Clin Oncol 27 2009 4536 4541
100. Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor-positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Paper presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12; San Antonio, TX. Abstract S1-6.
101. J. Baselga, M. Campone, M. Piccart Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
102. N. Turner, A. Tutt, A. Ashworth Hallmarks of 'BRCAness Nat Rev Cancer 4 2004 814 819
103. C.M. Annunziata, J. O'Shaughnessy Poly(ADP-ribose) polymerase as a novel therapeutic target in cancerPoly (ADP-ribose) polymerase as a novel therapeutic target in cancer Clin Cancer Res 16 2010 4517 4526
104. J. O'Shaughnessy, C. Osborne, J.E. Pippen Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 2011 205 214
105. P.C. Fong, T.A. Yap, D.S. Boss Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2010 2512 2519
106. E.R. Plummer Inhibition of poly(ADP-ribose) polymerase in cancer Curr Opin Pharmacol 6 2006 364 368
107. J. O'Shaughnessy, L.S. Schwartzberg, M.A. Danso A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) J Clin Oncol 29 suppl 2011 abstract 1007
108. X. Liu, Y. Shi, D.X. Maag Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor Clin Cancer Res 18 2012 510 523
109. A.G. Patel, S. De Lorenzo, K. Flatten Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro Clin Cancer Res 18 2012 1655 1662
110. A. Tutt, M. Robson, J.E. Garber Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244